TickerFacts.

Jyong Biotech Ltd. (MENS): R&D Expense

Annual figures by period end, from SEC filings.

$813.0K
Year ended 2025-12-31
$1.07M2023-12-31: $1.07M2024-12-31: $927.0K2025-12-31: $813.0K$813.0K
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$813.0K-12.3%2026-05-15, From 2025-01-01
2024-12-31$927.0K-13.4%2026-05-15, From 2024-01-01
2023-12-31$1.07Mn/a2026-05-15, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Jyong Biotech Ltd. (MENS)2025-12-31$813.0K-12.3%
Abvc Biopharma, Inc. (ABVC)2025-12-31$121.1K-32.5%
Annovis Bio, Inc. (ANVS)2025-12-31$25.22M+26.1%
Incannex Healthcare Inc. (IXHL)2025-06-30$10.75M-16.6%
Nexentis Technologies Inc. (NXTS)2025-12-31$179.0K-51.5%
Quoin Pharmaceuticals Ltd. (QNRX)2025-12-31$9.80M+172.1%
Evofem Biosciences, Inc. (EVFM)2024-12-31$1.84M-37.2%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$313.0K-52.4%
Phio Pharmaceuticals Corp. (PHIO)2025-12-31$4.62M+26.8%

Compare MENS, ABVC, ANVS, IXHL side by side · Screen every company in Pharmaceutical Preparations ↗